Publications
Detailed Information
Effectiveness and Safety of Sodium-Glucose Cotransporter2 Inhibitors Added to Dual or Triple Treatment in Patients with Type2 Diabetes Mellitus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Yesol | - |
dc.contributor.author | Jeon, Yoomin | - |
dc.contributor.author | Choi, Yoona | - |
dc.contributor.author | Chung, Tae Kyu | - |
dc.contributor.author | Lee, Howard | - |
dc.date.accessioned | 2023-12-26T04:27:16Z | - |
dc.date.available | 2023-12-26T13:27:59Z | - |
dc.date.issued | 2023-12-20 | - |
dc.identifier.citation | Diabetes Therapy, Vol.2023 | ko_KR |
dc.identifier.issn | 1869-6961 | - |
dc.identifier.uri | https://hdl.handle.net/10371/198739 | - |
dc.description.abstract | Introduction
We evaluated the effectiveness and safety of sodium-glucose cotransporter 2 inhibitor (SGLT2i) add-on treatment in patients with type 2 diabetes mellitus (T2DM) in the real-world setting. Methods This single-center retrospective study used the clinical database of Seoul National University Hospital in South Korea. Patients who received metformin monotherapy or combination therapy with ≥ 1 other oral hypoglycemic medication and had a baseline glycosylated hemoglobin (HbA1c) between 7.0% and 10.5% were included. Propensity score matching was applied between patients treated with and without SGLT2 inhibitors (SGLT2i and non-SGLT2i groups, respectively). Changes in HbA1c from baseline to week 26 were compared between the SGLT2i and non-SGLT2i groups, and risk of adverse events (AE) were also assessed. Results A total of 1106 patients were included. At week 26, HbA1c was significantly more reduced by 0.35 percentage points in the SGLT2i group than in the non-SGLT2i group (95% CI 0.30–0.41, P < 0.001). Likewise, the proportion of patients achieving HbA1c < 7% was also significantly higher (51.9% vs. 37.6%, P < 0.05) in the SGLT2i group than in the non-SGLT2i group. The risk of adverse events in the SGLT2i group was mostly comparable with those in the non-SGLT2i group except for diseases of the liver, pain, hypertensive diseases, and metabolic disorders, which showed significantly higher odds in the SGLT2i group. Conclusions SGLT2i add-on treatment is an effective and safe therapeutic option for patients with T2DM in the real-world practice setting. | ko_KR |
dc.description.sponsorship | This research and the journals Rapid Service Fee was supported by the BK21FOUR Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education (5120200513755). The study was supported by a grant of the Seoul National University Hospital (0620181130) | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | Springer | ko_KR |
dc.subject | Diabetes mellitus, type 2 | - |
dc.subject | Blood glucose | - |
dc.subject | Observational study | - |
dc.subject | Sodium-glucose transporter 2 inhibitors | - |
dc.subject | Hypoglycemic agents | - |
dc.title | Effectiveness and Safety of Sodium-Glucose Cotransporter2 Inhibitors Added to Dual or Triple Treatment in Patients with Type2 Diabetes Mellitus | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1007/s13300-023-01518-x | ko_KR |
dc.citation.journaltitle | Diabetes Therapy | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2023-12-24T04:16:31Z | - |
dc.citation.endpage | 10 | ko_KR |
dc.citation.startpage | 1 | ko_KR |
dc.citation.volume | 2023 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.